Loading organizations...

§ Private Profile · Copenhagen, Denmark
Robots that automate the everyday tasks of microbiologists.
Reshape Biotech has raised $29.0M across 3 funding rounds.
Key people at Reshape Biotech.
Reshape Biotech was founded in 2018 by Carl-Emil Grøn Fuglesang (Founder) and Daniel Storgaard (Founder) and Magnus Nyborg Madsen (Founder).
Reshape Biotech has raised $29.0M in total across 3 funding rounds.
Reshape Biotech builds lab robots that automate the everyday tasks of microbiologists, from filling plates to analyzing images.
Other companies try to sell “one lab robot that does everything”. But those robots become so complicated that they sit unused on the shelf. We build one robot for each function, which makes them easy to use.
Reshape Biotech is a Danish robotics company that automates routine microbiology lab tasks through specialized, modular robots designed for individual functions such as plate filling, imaging, and bioreactor handling. Their platform integrates robotics with AI-powered cloud analysis to streamline workflows, reduce manual labor, increase throughput, and minimize human error in biotechnology, healthcare, and industrial bio labs. By offering a Robotics-as-a-Service subscription model, Reshape Biotech enables faster, more cost-effective bio research and production, serving research institutions, biotech companies, and industrial bio sectors globally[1][2][5].
Founded in 2018 in Copenhagen, Denmark, Reshape Biotech was created by a team including co-founders Daniel Storgaard and Magnus Madsen, with early support from Y Combinator in 2021. The idea emerged from the need to simplify and automate repetitive microbiology tasks that traditionally required manual labor and were prone to inconsistency. Early traction came from developing a modular approach—building one robot per lab function rather than complex all-in-one systems—leading to adoption by major clients like Syngenta and the University of Oxford[3][6][7].
Reshape Biotech rides the wave of automation and digitalization in life sciences, addressing the growing demand for scalable, reproducible, and high-throughput biological experimentation. The timing is critical as biology increasingly shifts from manual science to engineering discipline, requiring robust data infrastructure and AI-driven insights. Market forces such as rising biotech R&D costs, the need for faster product development, and the expansion of microbial research underpin Reshape’s growth. Their platform not only accelerates individual labs but also contributes to building a comprehensive microbial data ecosystem, positioning them as a key enabler in the bioeconomy[2][6][7].
Looking ahead, Reshape Biotech aims to expand its global footprint, especially in the U.S. market, and enhance its AI models to cover broader experiment types and applications. Trends like increased adoption of Robotics-as-a-Service, AI integration in life sciences, and demand for reproducible, data-rich research environments will shape their trajectory. Their vision to become the "GitHub for microbes" by aggregating vast biobank data and enabling rapid discovery could transform bio R&D and production, making Reshape a pivotal player in accelerating biotech innovation worldwide[2][6]. Their focus on modular, user-friendly automation continues to lower barriers for labs, promising sustained growth and ecosystem impact.
Reshape Biotech has raised $29.0M across 3 funding rounds. Most recently, it raised $20.0M Series A in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2024 | $20M Series A | PER Falholt, Astanor Ventures | ACME Capital, Charlie Songhurst, Nicholas Francis, 21stbio, Acme, R7 Partners, Y Combinator | Announced |
| Feb 1, 2023 | $8M Seed | ACME Capital | Charlie Songhurst, Nicholas Francis, PER Falholt, FundersClub, Y Combinator | Announced |
| May 1, 2021 | $980K Seed | — | 7percent Ventures, ACME Capital, Chai Angels, Andreas Mihalovits, Charlie Kemper, Charlie Songhurst, Curtis Chambers, PIP Wilson, Will Brooks, Will Martin | Announced |
Key people at Reshape Biotech.
Reshape Biotech was founded in 2018 by Carl-Emil Grøn Fuglesang (Founder) and Daniel Storgaard (Founder) and Magnus Nyborg Madsen (Founder).
Reshape Biotech has raised $29.0M in total across 3 funding rounds.
Reshape Biotech's investors include Per Falholt, Astanor Ventures, ACME Capital, Charlie Songhurst, Nicholas Francis, 21stBio, ACME, R7 Partners, Y Combinator, FundersClub, 7percent Ventures, Chai Angels.